Autologous tissue, like skin grafts and flaps, remain the gold standard for wound coverage. However, when autologous tissue isn't practical, whether because of wound size, location, patient's medical status or other factors, then bioengineering skin can provide an alternative to wound coverage while also minimizing patient risk.
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This tissue engineering skin substituent is designed with tree layers with different porosity of collagen -alginate scaffolds that try to mimic the extracellular matrix of the skin. Due to the special template, these multilayer scaffolds allowed both fibroblasts and keratinocytes to growth and proliferate to form similar support with skin extracellular matrix. The deep layer is the most porous and is a hypoderm template. After a period of tissue ingrown, this layer is seeded with autologous fat cells. The middle layer had a medium porosity, is the dermal template and it will be seeded with fibroblasts. The superficial layer is designed to receive the keratinocytes. Preliminary result showed excellent biomechanical and biocompatibility properties and good integration with cultured fibroblast and keratinocytes. METHODS: SVF cells from 5 lipoaspirate were isolated and cultured onto porous hydroxyapatite scaffolds within a perfusion-based bioreactor system for 5 days. The medium was supplemented either with 10% FBS or 10% tPRP. The resulting constructs were inserted into devitalized bone cylinders mimicking AVN-affected bone. A ligated vascular bundle was inserted upon subcutaneous implantation of constructs in nude rats. After 1 and 8 weeks, vascularization and bone formation were analyzed.
PLATELET-RICH PLASMA VS. FETAL BOVINE SERUM IN ENGINEERING OF AXIALLY-VASCULARIZED OSTEOGENIC GRAFTS FROM HUMAN ADIPOSE-DERIVED CELLS TO TREAT AVASCULAR NECROSIS OF BONE

RESULTS:
After 1 week, neither maximal distance of vessels from the bundle nor vascular density was significantly different. However, FBS cultured grafts revealed significantly more human vessel (hCD34) and osteoclasts compared to tPRP cultured grafts. Overall macrophages and M2 macrophages were not different between FBS and tPRP cultured grafts. After 8 weeks in vivo, 3/5 samples from FBS culture and 1/5 sample from tPRP culture showed bone formation. Roughly 40% of the osteocytes were of human origin (36% from FBS and 42% from tPRP culture).
DISCUSSION:
Despite promising results in literature, replacement of FBS by tPRP resulted in a reduced capacity of bone formation in our series.
Further studies are necessary to analyze and improve the low bone formation capacity, possibly caused by the heterogeneity of the SVF donors and tPRP samples.
